AXA Diagnostics
ProdottiComunicati
Info
Chi siamo Dove siamo Contattaci Statistiche
Risorse

Sei in: Risorse: Comunicati Stampa:

Comunicati Stampa

Axa diagnostics named exclusive distributor for biosynex’s diagnostic products in italy

Rome, Italy and Strasbourg, France (sep.19, 2009) AXA Diagnostics Srl, a privately owned company that markets specialized diagnostic tests, announced today the signing of an exclusive distribution agreement with Biosynex. Under the terms of the agreement, AXA will market Biosynex’s rapid, membrane-based diagnostic tests in Italy.

Silvio Furino , President of AXA Diagnostics, said, “We are excited about our new relationship with Biosynex that allows us to market their rapid diagnostic kits on an exclusive basis in Italy. Biosynex products focus on autoimmunity, virology, tropical diseases, and emergency markers, which offers clinical laboratories and physicians simple tests that enable these healthcare professionals to get rapid information and allows them to improve patient monitoring. An example of one of Biosynex’s novel emergency marker assays is AMNIOQUICK®, a rapid strip test that can detect ruptures of the fetal membranes in pregnant women, providing a highly accurate and timely PROM (premature rupture of the membranes) diagnosis. IMMUNOQUICK® ELIFA EBV M assay, a rapid virology test for the detection of IgM antibodies against Epstein Barr Virus (EBV). This kit utilizes recombinant antigens, allowing the detection of specific antibodies earlier than other markers currently available on the market. This detection can occur 2 weeks earlier than other tests. IMMUNOQUICK® ELIFA CELIAC IgA is a rapid autoimmune test for the detection of IgA directed against recombinant human tissue transglutaminase (tTG) in serum. Anti-tTG IgA is a highly sensitive marker for celiac disease and detection of anti tTG IgA antibodies is now recognized as the main marker in case of suspected celiac disease in adults and children.” Furino further stated that “The addition of these unique rapid assays to our catalog is further evidence of our mission to provide specialized diagnostic tests that provide early and accurate diagnoses by healthcare professionals, which allows early intervention and ongoing monitoring of patients.”

About AXA Diagnostics
AXA Diagnostics is a private company located in Pomezia, Italy that markets specialized diagnostic tests. AXA Diagnostics sells over 300 diagnostic products on a direct basis in Italy and through a network of distributors in Europe. AXA Diagnostics has obtained certification for the management of its quality system according to the requirements of UNI EN ISO 13485:2004. More information on AXA Diagnostics is available at www.axadiagnostics.com.

About Biosynex

Biosynex is a French-based biotech company located in Strasbourg. Biosynex utilizes state-of-the-art manufacturing facilities to produce high quality immunochromatographic and immunofiltration tests.
Forward-Looking Statement Disclaimer
Various statements in this release concerning comments regarding future expectations, plans and prospects and constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any forward-looking statements represent AXA Diagnostics’ views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. AXA Diagnostics does not assume any obligation to update any forward-looking statements unless required by law.

 AXA Diagnostics Srl Company Contact:

Gianni Furino
AXA Diagnostics Srl
Via Campobello, 1
00040 Pomezia – ROMA (Italy)
Telephone: 39 06 912 511 79
Email: info@axadiagnostics.com